Company Overview of DUSA Pharmaceuticals Inc.
DUSA Pharmaceuticals, Inc., a vertically integrated dermatology company, develops and markets Levulan photodynamic therapy (PDT) and other products for common skin conditions primarily in the United States, Canada, and Korea. The company’s marketed products include Levulan Kerastick 20% Topical Solution with PDT, as well as the BLU-U brand light source for the treatment of non-hyperkeratotic actinic keratoses of the face or scalp. It also markets the BLU-U without Levulan PDT for the treatment of moderate inflammatory acne vulgaris and general dermatological conditions. The company was founded in 1991 and is headquartered in Wilmington, Massachusetts. As of December 19, 2012, DUSA Pharmaceut...
25 Upton Drive
Wilmington, MA 01887
Founded in 1991
Key Executives for DUSA Pharmaceuticals Inc.
Chief Executive Officer and President
Vice President of Operations
Chief Medical Officer and Vice President of Scientific Affairs
Compensation as of Fiscal Year 2012.
DUSA Pharmaceuticals Inc. Key Developments
DUSA Pharmaceuticals Inc. Announces Amendment of Certificate of Incorporation
Dec 21 12
DUSA Pharmaceuticals Inc. entered into an agreement and plan of merger on November 8, 2012 with Sun Pharmaceutical Industries Limited. The Merger became effective on December 20, 2012. In accordance with the provisions of the merger agreement pertaining to the top-up option, on December 20, 2012, the company amended its certificate of incorporation to designate an additional 35,000,000 shares of its capital stock as company common stock, so that as a result of such designation of shares of capital stock the company has 75,000,000 shares of authorized company common stock.
DUSA Pharmaceuticals Inc. Announces Board Changes
Dec 20 12
DUSA Pharmaceuticals Inc. entered into an Agreement and Plan of Merger on November 8, 2012 with Sun Pharmaceutical Industries Limited, and Caraco Acquisition Corp. Sun Pharma assigned its rights under the Merger Agreement as of November 16, 2012 to Caraco Pharmaceutical Laboratories Ltd. In accordance with the terms of the Merger Agreement and the Certificate of Merger, the directors of Sun Pharma immediately prior to the effective time, which were Messrs. Kal Sundaram and G.P. Singh, became the directors of the DUSA Pharmaceuticals Inc. following the Merger. Accordingly, on December 20, 2012, each of Messrs. Altomari, Bartash, Casdin, Doman, Haft, Hondros, Moliteus and Wurzer resigned from the Board.
DUSA Pharmaceuticals Inc.(NasdaqGM:DUSA) dropped from NASDAQ Composite Index
Dec 20 12
DUSA Pharmaceuticals Inc. will be removed from NASDAQ Composite Index
Similar Private Companies By Industry
Recent Private Companies Transactions
November 8, 2012